Astellas Forms India Sales Subsidiary; Gains Positive U.S. FDA Recommendation For Telavancin
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas is gearing up to launch its immunosuppressant Prograf in India in 2009 as a first-hand stab at penetrating into the Indian market with the Nov. 14 founding of its subsidiary, Astellas Pharma India Private Ltd. in Mumbai
You may also be interested in...
Astellas’ Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication
Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia
Astellas Launches Graceptor In Japan
Astellas announced it launched a once-daily capsule of immunosuppressant Graceptor (tacrolimus) Oct. 28 in Japan. The modified release drug uses the same ingredient as twice-daily Prograf. As patent protection for Astellas' blockbuster drug Prograf is to expire by December 2010, the company launched the modified release version to maximum profits. Graceptor is currently available in 19 countries, and is sold under the name Advagraf in Germany. An approval application in the U.S. is delayed as U.S. FDA requested the company to submit additional data to show efficacy. (Click here for more - Japanese language
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).